Kura Oncology Inc (NAS:KURA)
$ 11.04 -0.13 (-1.16%) Market Cap: 858.51 Mil Enterprise Value: 419.84 Mil PE Ratio: 0 PB Ratio: 2.03 GF Score: 42/100

Kura Oncology Inc ASH Virtual Investor Event Transcript

Dec 05, 2020 / 07:00PM GMT
Troy Edward Wilson
Kura Oncology, Inc. - Chairman, CEO & President

Good morning, good afternoon, everyone. My name is Troy Wilson, and I am the President and CEO of Kura Oncology. It's a pleasure to welcome all of you today to our investor event, where we'll be discussing the data that was just presented at the American Society of Hematology meeting just a few minutes ago.

I want to take a minute before we get started and just introduce the other participants on the line. I'm joined by Dr. Stephen Dale, Kura's Chief Medical Officer; Dr. Bridget Martell, Kura's Senior Scientific Advisor; Dr. Eunice Wang, one of the key investigators on the study from Roswell Park; Dr. Ghayas Issa from MD Anderson; Dr. Francis Burrows, who's our VP of Translational Research. Dr. Blake Tomkinson, our Head of Portfolio Strategy and Program Management. I believe I've covered all of the participants.

Before we get started, obviously, just need to make a forward-looking statement. The presentation and the comments that you hear today are going to be subject to forward-looking statement language. We would

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot